Summary
Out of 107 pts. treated with radio- and chemotherapy for low and high grade gliomas (TD: 45-65Gy), 3 cases developed pathologically documented radionecrosis (coagulative necrosis with minimal or no persistent tumor). Clinico-therapeutic modalities were analyzed for all cases and biologically equivalent doses were calculated according to NSD, ED and btu formulas. All cases of radionecrosis fell into the group of doses close to 60Gy/30fx./42d. and NSD=1758, ED=1340 and btu=1161. Isodose curve reconstruction on planes corresponding to histological sections of brains with radionecrosis demonstrated that doses received by areas of necrosis were higher than the calculated mid-plane doses in two cases. Clinical and autoptic incidence of radionecrosis were 2.8% and 10% respectively. High doses of steroids during RT seemed to offer some protection against radionecrosis, while number of chemotherapy cycles did not influence the risk of radionecrosis. A higher autoptic rate of irradiated gliomas is needed in order to obtain a better understanding of a number of unresolved problems.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Burger PC, Mahaley MS, Dudka L, Vogel FS: The morphologic effects of radiation administered therapeutically for intracranial gliomas. A postmortem study of 25 cases. Cancer 44: 1256–1272, 1979.
Schiffer D, Giordana MT, Soffietti R, Tarenzi L, Milani R, Vasario E, Paoletti P: Radio- and chemotherapy of malignant gliomas. Pathological changes in the normal nervous tissue. Acta Neurochir 58: 37–58, 1981.
Mikhael MA: Dosimetric considerations in the diagnosis of radiation necrosis of the brain. In: Gilbert HA and Kagan AR (eds) Radiation damage to the nervous system. A delayed therapeutic hazard. Raven Press, New York, 1980, pp59–91.
Marsa GW, Goffinet DR, Rubinstein LJ, Bagshaw MA: Megavoltage irradiation in the treatment of gliomas of the brain and spinal cord. Cancer 36: 1681–1689, 1975.
Marks JE, Baglan RJ, Prassad SC, Blank WF: Cerebral radionecrosis: incidence and risk in relation to dose, time, fractionation and volume. Int J Radiat Oncol Biol Phys 7: 243–252, 1981.
Deck MDF: Imaging techniques in the diagnosis of radiation damage to the central nervous system. In: HA Gilbert and AR Kagan (eds) Radiation damage to the nervous system. A delayed therapeutic hazard. Raven Press, New York, 1980, pp107–127.
Sheline GE: Irradiation injury to the human brain: a review of clinical experience. In: HA Gilbert and AR Kagan (eds) Radiation damage to the nervous system. A delayed therapeutic hazard. Raven Press, New York, 1980, pp39–58.
Pezner RD, Archambeau JO: Brain tolerance unit: a method to estimate risk of radiation brain injury for various dose schedules. Int J Radiat Oncol Biol Phys 7: 397–402, 1982.
Groothuis DR, Vick NA: Radionecrosis of the central nervous system: the perspective of the clinical neurologist and neuropathologist. In: HA Gilbert and AR Kagan (eds) Radiation damage to the nervous system. A delayed therapeutic hazard. Raven Press, New York, 1980, pp93–106.
Kramer S, Southard ME, Mansfield CM: Radiation effect and tolerance of the central nervous system. Front Rad Ther Oncol 6:332–345, 1972.
Ellis F: Relationship of biological effects to dose-time-fractionation factors in radiotherapy. In: M Ebert and A Howard (eds) Current Topics in Radiation Research. North Holland Publishers, Amsterdam, vol. 4, 1968, pp357–397.
Wara WM, Phillips TL, Sheline GE, Schwade JG: Radiation tolerance of the spinal cord. Cancer 35: 1558–1562, 1975.
Armitage P: Tests for linear trends in proportions and frequencies. Biometrics 11: 375–382, 1955.
Patronas NJ, DiChiro G, Brooks RA, Delapaz RL, Kornblith PL, Smith BH, Rizzoli HV, Kessler RM, Manning RG, Channing M, Wolf AP, O'Conner CM: Work in progress: (18F) Fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Radiology 144: 885–889, 1982.
Hochberg FH, Pruitt A: Assumptions in the radiotherapy of glioblastoma. Neurology 30: 907–911, 1980.
Shapiro WR: Treatment of neuroectodermal tumors. Ann Neurol 12: 231–237, 1982.
Green SB, Byar DP, Walker MD, Pistenmaa DA, Alexander E, Batzdorf U, Brooks WH, Hunt WE, Mealey J, Odom GL, Paoletti P, Ransohoff J, Robertson JT, Selker RG, Shapiro WR, Smith KR, Wilson CB, Strike TA: Comparison of Carmustine, Procarbazine, and high dose Methylprednisolone as addition to surgery and radiotherapy for the treatment of malignant gliomas. Cancer Treat. Rep 67: 121–132, 1983.
Burger PC, Dubois PJ, Schold SC, Smith KR, Odom GL, Crafts DC, Giangaspero F: Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J Neurosurg 58: 159–169, 1983.
Harris JR, Levene MB: Visual complications following irradiation for pituitary adenomas and craniopharyngiomas. Radiology 120: 167–171, 1978.
van der Kogel AJ: Late effects of radiation on the spinal cord (Ph. D. Thesis). Radiobiological Institute of the Organization for Health Research TNO, Rijswijk, The Netherlands, 1979.
Wigg DR, Koschel K, Hodgson GS: Tolerance of the mature human central nervous system to photon irradiation. Br J Radiol 54: 787–798, 1981.
Salazar ON, Rubin P, Feldstein ML, Pizzutiello R: High dose radiation therapy in the treatment of malignant gliomas: final report. Int J Radiat Oncol Biol Phys 5: 1733–1740, 1979.
Aristizabal SA, Boone ML, Laguna JF: Endocrine factors influencing radiation injury to central nervous tissue. Int J Radiat Oncol Biol Phys 5: 349–353, 1979.
Jellinger K: Pathologic effects of chemotherapy. In: MD Walker (ed) Oncology of the nervous system. Martinus Nijhoff Publishers, Boston, 1983, pp285–340.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Soffietti, R., Sciolla, R., Giordana, M.T. et al. Delayed adverse effects after irradiation of gliomas: clinicopathological analysis. J Neuro-Oncol 3, 187–192 (1985). https://doi.org/10.1007/BF02228896
Issue Date:
DOI: https://doi.org/10.1007/BF02228896